Gastroenterology
Volume 136, Issue 2 , Pages 486-495 , February 2009

2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B

  • Yun–Fan Liaw

      Affiliations

    • Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    • Corresponding Author InformationAddress requests for reprints to: Yun–Fan Liaw, MD, Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan. fax: (886) 3-3282824
    • ,
  • Edward Gane

      Affiliations

    • Department of Gastroenterology, Middlemore Hospital, Auckland, New Zealand
    • ,
  • Nancy Leung

      Affiliations

    • Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong, China
    • ,
  • Stefan Zeuzem

      Affiliations

    • Department of Medicine 1, J.W. Goethe Univeristy Hospital, Frankfurt, Germany
    • ,
  • Yuming Wang

      Affiliations

    • Xi Nan Hospital, Third Military Medical University, Chongqing, China
    • ,
  • Ching Lung Lai

      Affiliations

    • University Department of Medicine, Queen Mary Hospital, Hong Kong, China
    • ,
  • E. Jenny Heathcote

      Affiliations

    • Department of Medicine, Division of Gastroenterology, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Michael Manns

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • Natalie Bzowej

      Affiliations

    • Department of Liver Transplantation, California Pacific Medical Center, San Francisco, California
    • ,
  • Junqi Niu

      Affiliations

    • Department of Hepatology, First Hospital, University of Jilin, Guangzhou, China
    • ,
  • Steven–Huy Han

      Affiliations

    • Pfleger Liver Institute, UCLA School of Medicine, Los Angeles, California
    • ,
  • Seong Gyu Hwang

      Affiliations

    • Department of Internal Medicine, Pochon CHA University, Bundang Cha Hospital, Kyunggi-Do, Republic of Korea
    • ,
  • Yilmaz Cakaloglu

      Affiliations

    • Istanbul University, Istanbul, Turkey
    • ,
  • Myron J. Tong

      Affiliations

    • Phleger Liver Institute, Division of Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, California
    • ,
  • George Papatheodoridis

      Affiliations

    • 2nd Department of Internal Medicine, Athens University Medical School, Hippokration Hospital, Athens, Greece
    • ,
  • Yagang Chen

      Affiliations

    • First Affiliated Hospital, Zhejiang University, Hangzhou, China
    • ,
  • Nathaniel A. Brown

      Affiliations

    • Idenix Pharmaceuticals, Cambridge, Massachusetts
    • ,
  • Efsevia Albanis

      Affiliations

    • Novartis AG, Basel, Switzerland
    • ,
  • Karin Galil

      Affiliations

    • Idenix Pharmaceuticals, Cambridge, Massachusetts
    • ,
  • Nikolai V. Naoumov

      Affiliations

    • Novartis AG, Basel, Switzerland
    • ,
  • The GLOBE Study Group

Received 29 August 2008 ,Accepted 9 October 2008.

References 

  1. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005;25(Suppl 1):3–8
  2. Lok AS, McMahon BJ. Chronic hepatitis B—AASLD Practice Guidelines. Hepatology. 2001;34:1225–1241
  3. Fattovich G. Natural history of hepatitis B. J Hepatol. 2003;39(Suppl 1):S50–S58
  4. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73
  5. Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5:921–931
  6. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686
  7. Chen G, Lin W, Shen F, et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006;101:1797–1803
  8. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatology Int. 2008;2:263–283
  9. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–539
  10. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B (Asia Hepatitis Lamivudine Study Group). N Engl J Med. 1998;339:61–68
  11. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology. 1999;29:889–896
  12. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800–807
  13. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808–816
  14. Chang TT, Gish RG, De MR, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–1010
  15. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–1020
  16. Lai C-L, Gane E, Liaw Y-F, et al. A comparison of telbivudine and lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–2588
  17. Tenofovir EMEA approval. http://www.emea.europa.eu/humandocs/PDFs/EPAR/viread/H-419-PI-en.pdf
  18. Tenofovir FDA approval. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
  19. Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001;34:785–791
  20. Gauthier J, Bourne EJ, Lutz MW, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis. 1999;180:1757–1762
  21. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129:528–536
  22. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007;147:745–754
  23. Zollner B, Schafer P, Feucht HH, et al. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol. 2001;65:659–663
  24. Division of AIDS table for grading severity of adult adverse experiences. Bethesda, MD: National Institute of Allergy and Infectious Diseases; 1992;
  25. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther. 2004;9:679–693
  26. Agresti A, Hartzel J. Strategies for comparing treatments on a binary response with multi-centre data. Stat Med. 2000;19:1135–1139
  27. Liaw YF, Leung NWY, Chang TT, et al. Asian hepatitis lamivudine study group Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology. 2000;119:172–180
  28. Hou J, Yin Y-K, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology. 2008;47:447–454
  29. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133:1437–1444
  30. Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003;38:1267–1273
  31. Handziyannis S, Sevastianos V, Rapti IN, et al. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg negative chronic hepatitis B. Hepatology. 2006;44(Suppl 1):231A
  32. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687–696
  33. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743–1751
  34. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology. 2006;44:1656–1665
  35. Standring DN, Seifer M, Patty A, et al. HBV resistance determination from the telbivudine GLOBE registration trial. (abstr) J Hepatol. 2006;44(Suppl 2):S191
  36. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46:254–265
  37. Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007;45:307–313
  38. Ijaz S, Arnold C, Dervisevic S, et al. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. J Med Virol. 2008;80:1160–1170
  39. Liaw YF. Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how?. Hepatology. 2007;45:266–268
  40. Bridges EG. Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicity. (abstr) J Hepatol. 2006;44:S147

 Supported by Idenix Pharmaceuticals, Inc and Novartis Pharma AG. The corresponding author had full access to all of the data and takes full responsibility for the veracity of the data and analysis. Statistical analyses were performed by the study sponsor and independently by Quartesian, LLC (Princeton, NJ).

 The authors disclose the following: Y.–F.L. was a consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Novartis and has received grant/research support from Bristol–Myers Squibb, Idenix, Novartis, and Gilead. E.G. received consulting fees from Gilead, GlaxoSmithKline, Merck, and Novartis and honoraria from GlaxoSmithKline, Idenix, Novartis, and Roche. N.L. is a speaker for Bristol–Myers Squibb, GlaxoSmithKline, Novartis, and Schering–Plough. S.Z. received consulting fees and/or lecture from Bristol–Myers Squibb, Gilead, GlaxoSmithKline, Novartis, Roche, and Schering–Plough. C.L.L. has received research grants from Idenix-Novartis. E.J.H. served on advisory board for Axcan Pharma, Gilead Sciences, Hoffman-LaRoche, Novartis, Schering-Plough; received research grants/funding from Axcan Pharma, Bristol-Myers-Squibb, Gilead Sciences, GlaxoSmithKline, Hoffman-LaRoche, Idenix, Novartis, Pharmasset, Schering-Plough, Vertex. M.M. received research grants, honoraria, and/or consultancy fees from Bristol–Myers Squibb, Boehringer–Ingelheim, Gilead, Idenix, Novartis, Roche, Schering–Plough, GSK, and Valeant. N.B. has received funding from Roche, Vertex, Schering, Gilead, Pharmasset, Connatus, Idenix, Novartis and speaker bureau fees from Gilead and Novartis. S.–H.H. received grant support, consultancy fees, and lecture fees from Novartis/Idenix. S.G.H. received consulting fees from Bukwang and research grants from Idenix, Valeant, BMS, and GSK. G.P. serves on advisory boards for Bristol–Myers Squibb, Gilead Sciences, Hoffmann–La Roche, Idenix–Novartis, has received research grants (from participation in phase 2/3 trials) from Gilead Sciences and Idenix–Novartis, has received unrestricted research grants from Hoffmann–La Roche, and is a speaker for Bristol–Myers Squibb, Gilead Sciences, Hoffmann–La Roche, and Idenix–Novartis. N.A.B. and K.G. were employees of Idenix at the time of this study. E.A. was an employee of Novartis at the time of the study. N.V.N. is an employee of Novartis. J.N., M.J.T., Y.W., Y. Cakaloglu, and Y. Chen report no conflicts of interest.

PII: S0016-5085(08)01861-1

doi: 10.1053/j.gastro.2008.10.026

Gastroenterology
Volume 136, Issue 2 , Pages 486-495 , February 2009

Article Tools

* Image Usage & Resolution